Mammalian Cell Banking Market is segmented by Cell, Transient Expression Platforms, Inducible Expression Platforms, Stable Expression Platforms, Cell Bank
Industry: Healthcare
Published Date: January-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 251
Report ID: PMRREP31663
Global revenue from the market was about US$ 380.6 Million in 2022 with the worldwide market estimated to surge ahead at a CAGR of 13.8% to reach a valuation of around US$ 1.5 Billion by the end of 2033.
|
Mammalian Cell Banking Market Size (2023) |
US$ 436.0 Million |
|
Projected Market Value (2033) |
US$ 1.6 Billion |
|
Global Market Growth Rate (2023-2033) |
13.8% CAGR |
|
Market Share of Top 5 Countries |
64.6% |
According to Persistence Market Research, CHO cell segment of the market secured a market value of US$ 234.4 Million in 2022.
The market value for mammalian cell banking market was approximately 3.9% of the overall ~US$ 9.8 Billion of the global cell banking outsourcing market in 2022.
The global market recorded a historic CAGR of 12.7% in the last 7 years from 2015 to 2022.
Mammalian cells are cells that are separated from or developed from a mammal's tissue. Mammalian cell lines are utilized for practical biotechnology purposes in the production of viruses, proteins, and other things in addition to modelling biological systems and disease.
To support and promote research on cancer research, the National Cancer Institute and other institutions make significant research investments. These initiatives include The National Clinical Trials Network (NCTN), Cancer Moonshot, NCI Community Oncology Research Program (NCORP), NCI Genomic Data Commons (GDC), etc. This initiative taken by different organizations to support the market will boost sales in the forecast period.
Demand for preclinical studies is rising as the number of cancer cases increases. This is the primary driver of the mammalian cell banking market's growth. The biopharmaceutical industry will gain benefits from advances in cryopreservation technology. In the biopharmaceutical sector, mammalian cells are frequently used to produce recombinant therapeutic proteins. The biopharmaceutical industry uses mammalian cell lines as the host cells for the manufacturing of biologics.
The global mammalian cell banking market is thus likely to show high growth over the coming years with a CAGR of 13.8% and reach a global market size of around US$ 1,591.4 Million by 2033.
“Increasing focus on Oncological Research to Boost Market Growth”
As cancer cells are more receptive to in vitro culture, mammalian cell culture may have contributed the most to oncology research. For the scientific experiment, cell lines offer a perpetual stream of biological material. Government agencies in the South Asia region are funding more cancer research, expanding the market for companies that offer services for mammalian cell banks.
For instance, a Memorandum of Understanding (MoU) announced a signed partnership agreement between Cancer Research UK and the Department of Biotechnology (DBT) for the India-UK Cancer Research Initiative in November 2018. The Department of Biotechnology, Cancer Research UK (CRUK), and the Ministry of Science & Technology, India collaborated on a five-year India-UK cancer research initiative with a focus on developing cost-effective cancer treatments. In this five-year project, CRUK and DBT invested £5 million, and they actively seek out additional funding from other potential partners.
Cell banks are used to improve post-cryopreservation techniques to enhance cell recovery. Cryopreserved cell lines are offered in numerous vials to avoid repeated handling and reviving of cell lines during the research process, which could lead to contamination and genetic diversity. Hence, researchers will adopt the product more frequently for research propose.
This will promote the successful cryopreservation of cell lines, which is required for the development of effective processes for the production of biopharmaceutical products. Cryopreservation is also more important than conventional cell preservation techniques. This is the primary driver of the mammalian cell banking market's growth.
Governmental and non-governmental organizations are contributing more to cancer research in terms of financials. The market for mammalian cell banking will expand as a result. Over the projection period, this will present prospects for market size expansion.
“Lack of Skilled Professionals Limiting Market Growth”
Skilled professionals can contribute to innovation and growth in research and development by generating new knowledge in the field. Unfortunately, there is a shortage of skilled professionals engaged in research and developmental activities.
Low salary scales, challenging roles, and inadequate laboratory training are some of the main factors contributing to the lack of skilled professionals. Special laboratory training courses are necessary for handling cell line culture. As these courses are expensive for people, the growth of the market is hindered in the forecast period.
Less awareness of cell banking training programs resulted in a lack of experienced people in research laboratories, thus hampering the growth of the mammalian cell banking market. The Lack of skilled professionals and shortage of equipment & other accessories associated with research laboratories can negatively affect the mammalian cell banking market growth in developing regions.
Why is the U.S. Market Booming?
“Increasing Consolidation Activities among Key Players in U.S.”
The U.S. accounted for around 91.7% market share in the North American market in 2022 and is expected to over the forecast period.
The mammalian cell banking market is expanding with the growth of cancer research. Key manufacturers are concentrating to increase staff productivity and redefine flexibility, and efficiency.
An increase in service consolidation activities including sales and service agreements, collaborations, increased research and development activities, new service launches, and mergers & acquisitions by global and regional players in the U.S. are characteristic of the overall competition in the global market. These are the key factors aiding towards a prominent share of within U.S. market.
Will India be a Lucrative Market?
“Increasing Research and Development Activities by the Department of Biotechnology for Cancer Genomics”
India held around 4.4% market share of the global market in 2022 and market value is US$ 16.9 Million in 2022.
In India, cancer is a major public health problem. Every year, more than 1 million new cases of cancer are reported in India, this number is expected to rise due to the country's ageing population and changing lifestyle.
To conduct basic, translational, and clinical research as well as to develop new approaches to the prevention and treatment of disease, DBT (Department of Biotechnology) has formed resources available to multi-institutional networking programs, individual investigators and institutions through its Research & Development programs for cancer disease.
For instance, on 11 May 2020, to set up Virtual Network Centers (VNCs) in cancer immunology and immunotherapy, DBT launched a grant call. Due to all these initiatives taken by DBT for research and development activities in India, the country holds a significant share of the market.
How is Japan Emerging as a Prominent Market?
“Custom Service Offerings for Specific Needs”
Japan held a prominent market share of about 59.0% in the East Asia market in 2022.
The demand for specialized cell culture has increased due to the constantly changing needs of the research community to the point that the majority of vendors who are now providing these services cannot rely simply on sales from catalogue services in Japan. Because of the time and effort required to validate a customized cell line before usage in tests, research consumers frequently prefer particular solutions to meet the needs of the project. Vendors concentrate on building a robust distribution network to enable services to reach customers from their manufacturing plants in this region quickly.
Which Cell is Driving Growth of the Global Market?
“CHO is used in the Manufacturing of Therapeutic Proteins and Biologics”
The CHO segment held around 61.6% share of the global market in 2022, and tis expected to expand at a lucrative CAGR of 14.8% in forecast period.
In the development of biologics, Chinese Hamster Ovary (CHO) cells have become the benchmark. CHO cells became popular due to the low chromosome number and used to study genetics. The expression of high-quality protein has possible by recent developments in the bioprocessing of CHO cells to produce recombinant proteins and monoclonal antibodies.
CHO used in the commercial manufacture of therapeutic proteins as well as biological and medical research such as types of cancer. Due to all this positive advantages of CHO cell holds highest share in term of cell in the market.
Which Technology is Driving Growth of the Global Market?
“SEP Used in Bulk Production Activities”
The SEP (Stable Expression Platform) technology segment hold around 71.3% share of the global market in 2022.
Stable expression platform systems are used frequently in biopharmaceutical industry. For early stage manufacturers, where the most possible financial and commercial flexibility is required, cell line ownership, complications with IP, royalty payments and licensing may restrict alternatives for SEP. While various proteins can be produced quickly using transient technology in small quantities, the production of stable cell lines is necessary for producing larger quantities of material. Stable expression platform technologies often use auxotrophic selection or epigenetic engineering. Hence, due to all this positive factors SEP holds highest share in the market.
Which Application is Driving Growth of the Global Market?
“Ease of Recombinant Protein Production”
The WCB Application segment hold around 47.3% share of the global market in 2022.
Under specific cell culture conditions, working cell banks (WCB) are developed from the master cell bank (MCB). To verify that the WCB and MCB are genetically identical and to assure that the WCB is free of impurities, quality control tests using DNA profiling methods are carried out. WCB are clonal cell lines that have been formed and engineered to produce recombinant proteins, as further specified in a work order.
These mammalian cells are able to introduce post-translational modifications, optimal protein folding, and product assembly for recombinant proteins, all of which are required for biological function. The WCB are able to produce recombinant proteins.
Which End User Poses a Greater Adoption?
“Growing Research and Development Activities”
Biopharmaceutical companies hold the largest share of about 69.1% with a market value of around US$ 263.1 Million in 2022.
In terms of end users, recombinant therapeutic proteins is formed in the biopharmaceutical industry using mammalian cells. The biopharmaceutical industry uses mammalian cell lines as the host cells for the manufacturing of biologics. Biopharmaceutical companies use improved post-cryopreservation techniques to enhance cell recovery. This is a key factor for biopharmaceutical companies to hold highest share in terms of the end-user.
Key players concentrate on product launches, strategic alliances, and acquisitions to increase market presence. Apart from this, strategies of the manufacturers, include expansions such as the opening of new facilities in order to expand the developing new technology and innovative research and development capability of the company.
For instance:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies within the mammalian cell banking space, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2015-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Cell Type:
Technology:
Application:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 380.6 Million in 2022.
Sales of the market are set to witness a high growth at a CAGR of 13.8% and be valued at US$ 1.6 Billion by 2033.
Demand for market increased at a 12.7% CAGR from 2015 to 2022.
The U.S., Germany, Japan, U.K., and France account for the highest share of market, currently holding 64.6% market share.
The U.S. accounts for around 91.7% share of the North American market in 2022.
India accounted for around 4.4% share of the global market in 2022.
The Europe market is predicted to expand at 14.0% CAGR over the forecast period in global market.
The China market held a share of about 29.7% in the East Asia market in 2022, while Japan accounts for around 59.0% share in 2022.
The current value of the South Asia market is US$ 31.1 Million for the year, 2022.
The U.K. market held a share of about 18.8% in the Europe market in 2022.
